A phase II, randomized study on an investigational DTPw-HBV/Hib-MenAC conjugate vaccine administered to infants in Northern Ghana

PLoS ONE

Volumn 3, Issue 5, 2008, Pages

  Hodgson, Abraham ^a   Forgor, Abudulai Adams ^a   Chandramohan, Daniel ^b   Reed, Zarifah ^c   Binka, Fred ^d   Bevilacqua, Cornelia ^e   Boutriau, Dominique ^a   Greenwood, Brian ^b  

^a MINISTRY OF HEALTH   (Ghana)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

^d UNIVERSITY OF GHANA   (Ghana)

^e GlaxoSmithKline Biologicals ^*

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B MENINGOCOCCAL SEROGROUP A AND C CONJUGATED VACCINE; DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; MEASLES VACCINE; MENCEVAX AC; MENINGOCOCCUS VACCINE; POLIOMYELITIS VACCINE; POLYSACCHARIDE; YELLOW FEVER VACCINE; BACTERIUM ANTIBODY; DIPHTHERIA TOXOID; HAEMOPHILUS VACCINE; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; VACCINE;

ANEMIA; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; ASPIRATION PNEUMONIA; BRONCHOPNEUMONIA; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DEHYDRATION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DYSENTERY; ENTERITIS; EPIDEMIC MENINGITIS; FEMALE; GASTROENTERITIS; GHANA; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; IMPETIGO; INFANT; INJECTION SITE ERYTHEMA; MAJOR CLINICAL STUDY; MALARIA; MALE; NEISSERIA MENINGITIDIS; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SEPTICEMIA; SUDDEN INFANT DEATH SYNDROME; TREATMENT DURATION; TYPHOID FEVER; UPPER RESPIRATORY TRACT INFECTION; VACCINATION; BIOSYNTHESIS; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY;

NEISSERIA MENINGITIDIS;

ANTIBODIES, BACTERIAL; DIPHTHERIA TOXOID; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GHANA; HAEMOPHILUS VACCINES; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; INFANT; MALE; MENINGOCOCCAL VACCINES; VACCINES, COMBINED;

EID: 47749144791     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0002159     Document Type: Article

References (52)

1. Epidemics of meningococcal disease, African meningitis belt (2001) WHO, Weekly Epidemiological Record 76: 282-288.
2. Lapeysonnie L (1963) La meningite cérébrospinale en Afrique. Bull WHO 28: S3-114.
3. Greenwood B (1999) Manson Lecture. Meningococcal meningitis in Africa. Trans R Soc Trop Med Hyg 93: 341-353.
4. Vergano S, Heath P (2003) Neisseria meningitis serogroup A vaccines: an overview. Expert Rev Vaccines 2: 571-582.
5. Tikhomirov E, Santamaria M, Esteves K (1997) Meningococcal disease: public health burden and control. World health Stat Q 50: 170-177.
6. Balmer P, Miller E (2002) Meningococcal disease: how to prevent and how to manage. Curr Opin Infect Dis 15: 275-281.
7. Enhanced surveillance of epidemic meningococcal meningitis in Africa: a three-year experience (2005) WHO, Weekly Epidemiological Record. 80: 313-320.
8. Campagne G, Schuchat A, Djibo S, Ousséini A, Cissé L, et al. (1999) Epidemiology of bacterial meningitis in Niamey, Niger, 1981-96. Bull WHO 77: 499-508.
9. Nathan N, Borel T, Djibo A, Evans D, Djibo S, et al. (2005) Ceftriaxone as effective as long-acting chloramphenicol in short-course treatment of meningococcal meningitis during epidemics: a randomised non-inferiority study. Lancet 366: 308-313.
10. WHO: control of epidemic meningococcal disease (1998) WHO practical guidelines. 2nd edition (WHO/EMC/BAC/98.3). Available: www.who.int/ emc-documents/meningitis/docs/whoemcbac983.pdf. Accessed 7 April 2006.
11. Lingappa J, Al-Rabeah A, Hajjeh R, Mustafa T, Fatani A, et al. (2001) Serogroup W-135 disease during the Hajj, 2000. Emerg Infect Dis 9: 665-671.
12. Boisier P, Djibo S, Sidikou F, Mindadou H, Kairo K, et al. (2005) Epidemiological patterns of meningococcal meningitis in Niger in 2003 and 2004: under the threat of N. meningitidis serogroup W135. Trop Med Inter Health 10: 435-443.
13. Njanpop-Lafourcade BM, Parent du Châtelet I, Sanou O, Alonso JM, Taha MK (2005) The establishment of Neisseria meningitis serogroup W135 of the clonal complex ET-37/ST-11 as an epidemic clone and the presence of serogroup A isolate in Burkina Faso. Microbes Infect 7: 645-649.
14. Meningoccocal disease, Chad-update (2005) WHO, Weekly Epidemiological Record 80: 113-124.
15. Forgor AA, Leimkugel J, Hodgson A, Bugri A, Dangy JP, et al. (2005) Emergence of W135 meningococcal meningitis in Ghana. Trop Med Int Health 10: 1229-1234.
16. WHO Regional Office for Africa (2006) MDSC meningitis weekly bulletin, week 27-30.
17. Greenwood B, Smith A, Hassan-King M, Bijlmer H, Shenton F, et al. (1986) The efficacy of meningococcal polysaccharide vaccine in preventing group A meningococcal disease in The Gambia, West Africa. Trans R Soc Trop Med Hyg Correspondence 80: 1006-1007.
18. WHO fact sheet N 141 (2006) Available: http://www.who.int/mediacentre/ factsheets/fs141/en. Accessed 7 April 2006.
19. Robbins J, Schneerson R, Gotschlich EC, Mohammed I, Nasidi A, et al. (2003) Meningococcal meningitis in sub-Saharan Africa: the case for mass and routine vaccination with available polysaccharide vaccines. Bulletin of the World Health Organization 81: 745-750.
20. Richmond P, Borrow R, Miller E, Clark S, Sadler F, et al. (1999) Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory. J Infect Dis 179: 1569-1572.
21. Richmond P, Borrow R, Findlow J, Martin S, Thornton C, et al. (2001) Evaluation of De-O-acetylated meningococcal C polysaccharide-tetanus toxoid conjugate vaccine in infancy: reactogenicity, immunogenicity, immunologic priming, and bactericidal activity against O-acetylated and De-O-acetylated serogroup C strains. Infect Immun 69: 2378-2382.
22. Trotter C, Andrews N, Kaczmarski E, Miller E, Ramsay M (2004) Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 364: 365-367.
23. Maiden M, Stuart J (2002) Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 359: 1829-1831.
24. Pichichero ME (2005) Meningococcal conjugate vaccines. Expert Opinion Biol Ther 5: 1475-1489.
25. Chippaux JP, Garba A, Ethevenaux C, Campagne G, de Chabalier F, et al. (2004) Immunogenicity, safety, and memory of different schedules of Neisseria meningitidis A/C-diphtheria toxoid conjugate vaccine in infants in Niger. Vaccine 22: 3303-3311.
26. Twumasi P, Kumah S, Leach A, O'Dempsey TJ, Ceesay SJ, et al. (1995) A trial of a group A plus group C meningococcal polysaccharide-protein conjugate vaccine in African infants. J Infect Dis 171: 632-638.
27. Leach A, Twumasi P, Kumah S, Banya WS, Jaffar S, et al. (1997) Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine. J Infect Dis 175: 200-204.
28. MacLennan J, Obaro S, Deeks J, Williams D, Pais L, et al. (2001) Immunologic memory 5 years after meningococcal A/C conjugate vaccination in infancy. J Infect Dis 183: 97-104.
29. Meningitis Vaccine Project Available: http://www.meningvax.org/. Accessed 7 April 2006.
30. Gatchalian S, Palestroque E, De Vleeschauwer I, Han HH, et al. (2007) The development of a new heptavalent diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C vaccine: a randomized dose-ranging trial of the conjugate vaccine components. Int J Infect Dis (in press).
31. National AIDS/STI Control Programme (2007) HIV Sentinel Survey 2006 Report, Republic of Ghana and Ghana Health Services: p 52.
32. Leimkugel J, Hodgson A, Forgor AA, Pflüger V, Dangy JP, et al. (2007) Clonal waves of neisseria colonization and disease in the African meningitis belt: Eight year longitudinal study in Northern Ghana. PLoS Med 4(3): e101. doi10.1371/journal.pmed.0040101.
33. Ghana's Expanded Programme on Immunization in Ghana. Available: http://www.who.int/countries/gha/publications/EPI_profile.pdf. Accessed 7 April 2006.
34. Maslanka SE, Gheesling LL, Libutti DE, Donaldson KB, Harakeh HS, et al. (1997) Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. Clin Diagn Lab Immunol 4: 156-167.
35. Borrow R, Balmer P, Miller E (2005) Meningococcal surrogates of protection-serum bactericidal antibody activity. Vaccine 23: 2222-2227.
36. Peltola H (1998) Meningococcal vaccines. Current status and future possibilities Drugs 55: 347-366.
37. Gheesling LL, Carlone GM, Pais LB, Holder PF, Maslanka SE, et al. (1994) Multicenter comparison of Neisseria meningitidis serogroup C anti-capsular polysaccharide antibody levels measured by a standardized Enzyme-Linked Immunosorbent Assay. J Clin Microbiol 32: 1475-1482.
38. Miyamura K, Nisho S, Ito A, Murata R, Kono R (1974) Micro cell culture method for determination of diphtheria toxin and antitoxin concentrations using VERO cells: I. Studies on factors affecting the toxin and antitoxin titration. J Biol Stand 2: 189-201.
39. Amir J, Louie L, Granoff D (2005) Naturally-acquired immunity to Neisseria meningitidis group A. Vaccine 23: 977-983.
40. Mueller JE, Yaro S, Traore Y, Sangare L, Tarnagda Z, Njanpop-Lafourcade BM, Borrow R, Gessner BD (2006) Neisseria meningitidis serogroups A and W-135: carriage and immunity in Burkina Faso,2003. J Infect. Dis 193: 812-20.
41. Yaro S, Traoré Y, Tarnagda Z, Sangaré L, NjanpopLafourcade BM, Drabo A, Findlow H, Borrow R, Nicolas P, Gessner BD, Mueller JE (2007) Meningococcal carriage and immunity in western Burkina Faso, 2003. Vaccine 25 Suppl 1: A42-6.
42. Blakebrough IS, Gilles HM (1980) The effect of rifampicin on meningococcal carriage in family contacts in northern Nigeria. J Infect 2(2): 137-143.
43. Greenwood B, Smith AW, Hassan-King M, Bijmler HA, Shenton FC, et al. (1986) The efficacy of meningococcal polysaccharide vaccine in preventing group A meningococcal disease in The Gambia, West Africa. Trans R Soc Trop Med Hyg 80: 1006-1007.
44. De Wals P, Deceuninck G, De Serres G, Boivin JF, Duval B, et al. (2005) Effectiveness of serogroup C meningococcal polysaccharide vaccine: results from a case-control study in Quebec. Clin Infect Dis 40: 1116-1122.
45. Southern J, Crowley-Luke A, Borrow R, Andrews N, Miller E (2005) Immunogenicity of one, two or three doses of a meningococcal C conjugate vaccine conjugated to tetanus toxoid, given as a three-dose primary vaccination course in UK infants at 2, 3 and 4 months of age with acellular pertussis-containing DTP/Hib vaccine. Vaccine 24: 215-219.
46. Immunization policy. Global Programme for vaccines and immunization (1996) Expanded Program on Immunization. (WHO/EPI/GEN/95.03 Rev 1) p : 19. Available: http://whqlibdoc.who.int/hq/1995/ WHO_EPI_GEN_95.03_REV.1.pdf. Accessed 7 April 2006.
47. Kitchin N, Southern J, Morris R, Hemme F, Thomas S, et al. (2007) Evaluation of a diphtheria-tetanus-acellular pertussis -inactivated poliovirus-Haemophilus influenzae type b vaccine given concurrently with meningococcal group C conjugate vaccine at 2, 3 and 4 months of age. Arch Dis Child 92: 11-16.
48. Usen S, Milligan P, Ethevenaux C, Greenwood B, Mulholland K (2000) Effect of fever on the serum antibody response of Gambian children to Haemophilus influenzae type b conjugate vaccine. Pediatr Infect Dis J 19: 444-449.
49. Williamson WA, Greenwood BM (1978) Impairement of the immune response to vaccination after acute malaria. Lancet 311: 1328-1329.
50. Aspinall S, Kocks D (1998) Immunogenicity of a low-cost hepatitis B vaccine in the South African Expanded Programme on Immunisation. S Afr Med J 88: 36-39.
51. Nyarko P, Wontuo P, Wak G, Chirawurah D, Welaga P, et al. (2001) The Navrongo demographic surveillance system 2001 report to the Rockefeller Foundation. Community health and family planning project documentation note number 45. Navrongo, Upper East Region, Ghana.
52. Carter JA, Neville BGR, White S, Ross AJ, Otieno G, et al. (2004) Increased Prevalence of Epilepsy Associated with Severe Falciparum Malaria in Children. Epilepsia 45: 978-981.